Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib and PD-1 Inhibitors in MSS Colorectal Cancer
NCT04110093Phase 2Unknown
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Mar 2019
- Primary completion
- Aug 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of regorafenib, nivolumab, camrelizumab, sintilimab and toripalimab in colorectal cancer (CRC), sponsored by Shanghai Changzheng Hospital. Primary endpoints: Objective Response Rate at 2 months and Progression-Free Survival at 2 months. Status: unknown.
02
Drugs
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04110093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04110093.